Zhiyong Ding Departments of Systems Biology, UT MD Anderson Cancer Center, USA
1 protocol

Huifang Guo Departments of Systems Biology, UT MD Anderson Cancer Center, USA
1 protocol

Philip L Lorenzi
  • Departments of Bioinformatics & Computational Biology, UT MD Anderson Cancer Center, USA
  • 1 Author merit


Ph.D. in Pharmaceutics, University of Michigan, Ann Arbor, MI, 2004

Current position

Co-Director, The Proteomics and Metabolomics Core Facility, MD Anderson Cancer Center, Houston, TX (01/2014-present)
Supervisor of Laboratory and Research, Department of Bioinformatics & Computational Biology, MD Anderson Cancer Center, Houston, TX (04/2009 -present)


  1. Chaluvally-Raghavan, P., Zhang, F., Pradeep, S., Hamilton, M. P., Zhao, X., Rupaimoole, R., Moss, T., Lu, Y., Yu, S., Pecot, C. V., Aure, M. R., Peuget, S., Rodriguez-Aguayo, C., Han, H. D., Zhang, D., Venkatanarayan, A., Krohn, M., Kristensen, V. N., Gagea, M., Ram, P., Liu, W., Lopez-Berestein, G., Lorenzi, P. L., Borresen-Dale, A. L., Chin, K., Gray, J., Dusetti, N. J., McGuire, S. E., Flores, E. R., Sood, A. K. and Mills, G. B. (2014). Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 26(6): 863-879.
  2. Purwaha, P., Silva, L. P., Hawke, D. H., Weinstein, J. N. and Lorenzi, P. L.* (2014). An artifact in LC-MS/MS measurement of glutamine and glutamic acid: in-source cyclization to pyroglutamic acid. Anal Chem 86(12): 5633-5637. *Corresponding author.
  3. Chan, W. K., Lorenzi, P. L.*, Anishkin, A., Purwaha, P., Rogers, D. M., Sukharev, S., Rempe, S. B. and Weinstein, J. N. (2014). The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood 123(23): 3596-3606. *Co-first author and corresponding author.
  4. Purwaha, P., Lorenzi, P. L.*, Silva, L. P., Hawke, D. H. and Weinstein, J. N. (2014). Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cells. Metabolomics 10(5): 909-919. *Co-first author and corresponding author.
  5. Lorenzi, P. L.*, Claerhout, S., Mills, G. B. and Weinstein, J. N. (2014). A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy. Autophagy 10(7): 1316-1326. *Co-first author and corresponding author.
  6. Cancer Genome Atlas Research, N. (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492): 315-322.
  7. Weinstein, J. N. and Lorenzi, P. L. (2013). Cancer: Discrepancies in drug sensitivity. Nature 504(7480): 381-383.
  8. Cancer Genome Atlas Research, N., Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C. and Stuart, J. M. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10): 1113-1120.
  9. Silva, L. P., Lorenzi, P. L.*, Purwaha, P., Yong, V., Hawke, D. H. and Weinstein, J. N. (2013). Measurement of DNA concentration as a normalization strategy for metabolomic data from adherent cell lines. Anal Chem 85(20): 9536-9542. *Co-first author.
  10. Guo, H., Gao, M., Lu, Y., Liang, J., Lorenzi, P. L., Bai, S., Hawke, D. H., Li, J., Dogruluk, T., Scott, K. L., Jonasch, E., Mills, G. B. and Ding, Z. (2014). Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene 33(26): 3463-3472. 
  11. Claerhout, S., Lorenzi, P. L.*, Weinstein, J. N. and Mills, G. B. (2011). Modulation of Autophagy and Its Potential for Cancer Therapy. Drugs Future 36(12).*Co-first and corresponding author
  12. Liu, H., D'Andrade, P., Fulmer-Smentek, S., Lorenzi, P., Kohn, K. W., Weinstein, J. N., Pommier, Y. and Reinhold, W. C. (2010). mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 9(5): 1080-1091. 
  13. Reinhold, W. C., Reimers, M. A., Lorenzi, P., Ho, J., Shankavaram, U. T., Ziegler, M. S., Bussey, K. J., Nishizuka, S., Ikediobi, O., Pommier, Y. G. and Weinstein, J. N. (2010). Multifactorial regulation of E-cadherin expression: an integrative study. Mol Cancer Ther 9(1): 1-16.
  14. Jobson, A. G., Lountos, G. T., Lorenzi, P. L., Llamas, J., Connelly, J., Cerna, D., Tropea, J. E., Onda, A., Zoppoli, G., Kondapaka, S., Zhang, G., Caplen, N. J., Cardellina, J. H., 2nd, Yoo, S. S., Monks, A., Self, C., Waugh, D. S., Shoemaker, R. H. and Pommier, Y. (2009). Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J PharmacolExpTher 331(3): 816-826.
  15. Lorenzi, P. L., Reinhold, W. C., Varma, S., Hutchinson, A. A., Pommier, Y., Chanock, S. J. and Weinstein, J. N. (2009). DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 8(4): 713-724.
  16. Lorenzi, P. L. and Weinstein, J. N. (2009). Asparagine synthetase: a new potential biomarker in ovarian cancer. Drug News Perspect 22(1): 61-64.
  17. Lorenzi, P. L.,Ryan,M.C.,Ikediobi, O.N., and Weinstein, J.N.(2008).ASNS (asparagine synthetase). Atlas Genet CytogenetOncolHaematol.
  18. Lorenzi, P. L., Llamas, J., Gunsior, M., Ozbun, L., Reinhold, W. C., Varma, S., Ji, H., Kim, H., Hutchinson, A. A., Kohn, E. C., Goldsmith, P. K., Birrer, M. J. and Weinstein, J. N. (2008). Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 7(10): 3123-3128.
  19. Blower, P. E., Verducci, J. S., Lin, S., Zhou, J., Chung, J. H., Dai, Z., Liu, C. G., Reinhold, W., Lorenzi, P. L., Kaldjian, E. P., Croce, C. M., Weinstein, J. N. and Sadee, W. (2007). MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6(5): 1483-1491.
  20. Martin, S. E., Jones, T. L., Thomas, C. L., Lorenzi, P. L., Nguyen, D. A., Runfola, T., Gunsior, M., Weinstein, J. N., Goldsmith, P. K., Lader, E., Huppi, K. and Caplen, N. J. (2007). Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res 35(8): e57.
  21. Miao, Z. H., Player, A., Shankavaram, U., Wang, Y. H., Zimonjic, D. B., Lorenzi, P. L., Liao, Z. Y., Liu, H., Shimura, T., Zhang, H. L., Meng, L. H., Zhang, Y. W., Kawasaki, E. S., Popescu, N. C., Aladjem, M. I., Goldstein, D. J., Weinstein, J. N. and Pommier, Y. (2007). Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 67(18): 8752-8761.
  22. Lorenzi, P. L., Reinhold, W. C., Rudelius, M., Gunsior, M., Shankavaram, U., Bussey, K. J., Scherf, U., Eichler, G. S., Martin, S. E., Chin, K., Gray, J. W., Kohn, E. C., Horak, I. D., Von Hoff, D. D., Raffeld, M., Goldsmith, P. K., Caplen, N. J. and Weinstein, J. N. (2006). Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 5(11): 2613-2623. 
  23. Lorenzi, P. L., Landowski, C. P., Brancale, A., Song, X., Townsend, L. B., Drach, J. C. and Amidon, G. L. (2006). N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole. Drug MetabDispos 34(6): 1070-1077. *Figure selected for journal cover
  24. Landowski, C. P., Lorenzi, P. L., Song, X. and Amidon, G. L. (2006). Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J PharmacolExpTher 316(2): 572-580.
  25. Lorenzi, P. L., Landowski, C. P., Song, X., Borysko, K. Z., Breitenbach, J. M., Kim, J. S., Hilfinger, J. M., Townsend, L. B., Drach, J. C. and Amidon, G. L. (2005). Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J PharmacolExpTher 314(2): 883-890.
  26. Song, X., Lorenzi, P. L., Landowski, C. P., Vig, B. S., Hilfinger, J. M. and Amidon, G. L. (2005). Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm 2(2): 157-167.
  27. Landowski, C. P., Song, X., Lorenzi, P. L., Hilfinger, J. M. and Amidon, G. L. (2005). Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res 22(9): 1510-1518.
  28. Song, X., Vig, B. S., Lorenzi, P. L., Drach, J. C., Townsend, L. B. and Amidon, G. L. (2005). Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem 48(4): 1274-1277.
  29. Kim, I., Song, X., Vig, B. S., Mittal, S., Shin, H. C., Lorenzi, P. J. and Amidon, G. L. (2004). A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm 1(2): 117-127.
  30. Vig, B. S., Lorenzi, P. J., Mittal, S., Landowski, C. P., Shin, H. C., Mosberg, H. I., Hilfinger, J. M. and Amidon, G. L. (2003). Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 20(9): 1381-1388.
  31. El-Qisairi, A. K., Qaseer, H. A., Katsigras, G., Lorenzi, P., Trivedi, U., Tracz, S., Hartman, A., Miller, J. A. and Henry, P. M. (2003). New palladium(II)-catalyzed asymmetric 1,2-dibromo synthesis. Org Lett 5(4): 439-441.
  32. Shu, C., Shen, H., Teuscher, N. S., Lorenzi, P. J., Keep, R. F. and Smith, D. E. (2002). Role of PEPT2 in peptide/mimetic trafficking at the blood-cerebrospinal fluid barrier: studies in rat choroid plexus epithelial cells in primary culture. J PharmacolExpTher 301(3): 820-829.
1 Protocol published
Nanofluidic Proteomic Immunoassay
Authors:  Huifang Guo, Philip L Lorenzi and Zhiyong Ding, date: 07/20/2015, view: 4005, Q&A: 0
Nanofluidic proteomic immunoassay (NIA), consisting of isoelectric focusing followed by sensitive chemiluminescence detection, has the potential to quantitatively characterize protein post-translational modifications that cause shifts in isoelectric ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.